{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:03:22Z","timestamp":1791295402179,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T00:00:00Z","timestamp":1491868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ygyno.2017.04.004","type":"journal-article","created":{"date-parts":[[2017,4,22]],"date-time":"2017-04-22T11:00:17Z","timestamp":1492858817000},"page":"196-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":376,"title":["HPV vaccines \u2013 A review of the first decade"],"prefix":"10.1016","volume":"146","author":[{"given":"Diane M.","family":"Harper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie R.","family":"DeMars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.04.004_bb0005","unstructured":"How many cancers are linked with HPV each year? [Internet] Available from www.cdc.gov\/cancer\/hpv\/statistics\/cases.htm."},{"key":"10.1016\/j.ygyno.2017.04.004_bb0010","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ijc.29670","article-title":"Cancer incidence in five continents: inclusion criteria highlights from volume X and the global status of cancer registration","volume":"137","author":"Bray","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.04.004_bb0015","series-title":"Textbook of Gynaecological Oncology","first-page":"247","article-title":"Chapter 29 bivalent HPV vaccine approved for cervical cancer prevention in females","author":"Fernandez","year":"2016"},{"key":"10.1016\/j.ygyno.2017.04.004_bb0020","series-title":"Textbook of Gynaecological Oncology","first-page":"279","article-title":"Chapter 30 quadrivalent and nonavalent HPV vaccine approved for males and females for HPV associated diseases","author":"LaJoie","year":"2016"},{"key":"10.1016\/j.ygyno.2017.04.004_bb0025","unstructured":"Gardasil9 package insert [Internet] Available from http:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm426457.pdf."},{"key":"10.1016\/j.ygyno.2017.04.004_bb0030","series-title":"Cervarix Package Insert","year":"2009"},{"key":"10.1016\/j.ygyno.2017.04.004_bb0035","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV 1\/618 L1 VLP vaccine formulated with the MPL\/aluminum salt combination (AS04) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.ygyno.2017.04.004_bb0040","series-title":"Primary End-points for Prophylactic HPV Vaccine Trials","volume":"vol. 7","author":"IARC HPV Working Group Report","year":"2013"},{"issue":"10","key":"10.1016\/j.ygyno.2017.04.004_bb0045","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","author":"Olsson","year":"2009","journal-title":"Hum. Vaccin."},{"issue":"12","key":"10.1016\/j.ygyno.2017.04.004_bb0050","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.4161\/hv.36121","article-title":"Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18\u201345years: end-of-study analysis of a phase III randomized trial","volume":"10","author":"Einstein","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"issue":"12","key":"10.1016\/j.ygyno.2017.04.004_bb0055","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.4161\/hv.36117","article-title":"Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18\u201345years: follow-up through month 48 in a phase III randomized study","volume":"10","author":"Einstein","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"issue":"12","key":"10.1016\/j.ygyno.2017.04.004_bb0060","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.4161\/hv.7.12.18282","article-title":"Comparison of the immunogenicity of the human papillomavirus (HPV)-16\/18 vaccine and the HPV-6\/11\/16\/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18\u201345years","volume":"7","author":"Einstein","year":"2011","journal-title":"Hum. Vaccin."},{"issue":"12","key":"10.1016\/j.ygyno.2017.04.004_bb0065","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4161\/hv.7.12.18281","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 vaccine and HPV-6\/11\/16\/18 vaccine: follow-up from months 12\u201324 in a Phase III randomized study of healthy women aged 18\u201345years","volume":"7","author":"Einstein","year":"2011","journal-title":"Hum. Vaccin."},{"issue":"10","key":"10.1016\/j.ygyno.2017.04.004_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140926","article-title":"Relationship between humoral immune responses against HPV16, HPV18, HPV31 and HPV45 in 12\u201315year old girls receiving Cervarix\u00ae or Gardasil\u00ae vaccine","volume":"10","author":"Godi","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ygyno.2017.04.004_bb0075","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4years post-vaccination","volume":"10","author":"Naud","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"issue":"8","key":"10.1016\/j.ygyno.2017.04.004_bb0080","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/CVI.00133-15","article-title":"Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine","volume":"22","author":"Nygard","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.ygyno.2017.04.004_bb0085","unstructured":"Statistical Review of Gardasil9-[Internet] http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM428669.pdf."},{"issue":"26","key":"10.1016\/j.ygyno.2017.04.004_bb0090","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine","volume":"25","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.ygyno.2017.04.004_bb0095","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1080\/21645515.2015.1011570","article-title":"The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine","volume":"11","author":"Gilca","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"issue":"48","key":"10.1016\/j.ygyno.2017.04.004_bb0100","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1016\/j.vaccine.2015.08.059","article-title":"Safety and immunogenicity of a 9-valent HPV vaccine in females 12\u201326years of age who previously received the quadrivalent HPV vaccine","volume":"33","author":"Garland","year":"2015","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.ygyno.2017.04.004_bb0105","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/infdis\/jiw046","article-title":"Impact and cost-effectiveness of 3 doses of 9-valent human papillomavirus (HPV) vaccine among US females previously vaccinated with 4-valent HPV vaccine","volume":"213","author":"Chesson","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ygyno.2017.04.004_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030138","article-title":"Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modeling analyses","volume":"3","author":"Barnabas","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.ygyno.2017.04.004_bb0115","unstructured":"World Health Organization website Immunization Vaccines and Biologicals-Human Papillomavirus [Internet]. http:\/\/www.who.int\/immunization\/diseases\/hpv\/en\/."},{"key":"10.1016\/j.ygyno.2017.04.004_bb0120","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination \u2014 updated recommendations of the Advisory Committee on Immunization Practices","volume":"65","author":"Meites","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"11","key":"10.1016\/j.ygyno.2017.04.004_bb0125","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial","volume":"6","author":"Safaeian","year":"2013","journal-title":"Cancer Prev. Res. (Phila.)"},{"issue":"1","key":"10.1016\/j.ygyno.2017.04.004_bb0130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(15)00414-3","article-title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","volume":"17","author":"Sankaranarayanan","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2017.04.004_bb0135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jinf.2015.02.005","article-title":"Inconclusive evidence for non-inferior immunogenicity of two compared with three dose HPV immunization schedules in preadolescent girls: a meta-analysis","volume":"71","author":"Donken","year":"2015","journal-title":"J. Infect."},{"issue":"14","key":"10.1016\/j.ygyno.2017.04.004_bb0140","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/jama.2011.407","article-title":"Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized non-inferiority trial","volume":"305","author":"Neuzil","year":"2011","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ygyno.2017.04.004_bb0145","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/infdis\/jit363","article-title":"Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose","volume":"208","author":"LaMontagne","year":"2013","journal-title":"J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.ygyno.2017.04.004_bb0155","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1080\/21645515.2015.1050570","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9\u201314years: results to month 12 from a randomized trial","volume":"11","author":"Leung","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"issue":"22","key":"10.1016\/j.ygyno.2017.04.004_bb0160","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ygyno.2017.04.004_bb0165","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24\u201345years of age","volume":"105","author":"Castellsagu\u00e9","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2017.04.004_bb0170","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/1471-0528.13070","article-title":"Persistence of immune responses to the HPV-16\/18 AS04-adjuvanted vaccine in women aged 15\u201355years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study","volume":"122","author":"Schwarz","year":"2015","journal-title":"BJOG"},{"issue":"9961","key":"10.1016\/j.ygyno.2017.04.004_bb0175","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(14)60920-X","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"384","author":"Skinner","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2017.04.004_bb0180","series-title":"Persistence of Immune Response 10years After Administration of the Human Papillomavirus (HPV) 16\/18 AS04-adjuvanted Vaccine to Women Aged 15\u201355Years","author":"Schwarz","year":"2016"},{"issue":"11","key":"10.1016\/j.ygyno.2017.04.004_bb0185","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.04.004_bb0190","unstructured":"Statistical Review of Gardasil9 [Internet] http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM429166.pdf."},{"key":"10.1016\/j.ygyno.2017.04.004_bb0195","doi-asserted-by":"crossref","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","author":"FUTURE I\/II Study Group","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.ygyno.2017.04.004_bb0200","unstructured":"Medical Officer Review of Gardasil by FDA in 2008 [Internet] http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM111274.pdf."},{"issue":"8","key":"10.1016\/j.ygyno.2017.04.004_bb0205","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2017.04.004_bb0210","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV associated genital diseases in young women","volume":"102","author":"Munoz","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.04.004_bb0215","series-title":"29th International Papillomavirus Conference and Public Health & Clinical Workshops","article-title":"Efficacy of a novel 9-valent HPV L1 vaccine against disease irrespective of HPV type","author":"Giuliano","year":"2014"},{"issue":"1","key":"10.1016\/j.ygyno.2017.04.004_bb0220","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24\u201345years of age","volume":"105","author":"Castellsague","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.04.004_bb0225","series-title":"National, State and local Area Vaccination Coverage Among Adolescents Aged 13\u201317years \u2013 United States","year":"2009"},{"issue":"9686","key":"10.1016\/j.ygyno.2017.04.004_bb0230","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ygyno.2017.04.004_bb0235","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2017.04.004_bb0240","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CVI.00591-14","article-title":"Efficacy of human papillomavirus 16 and 18 (HPV-16\/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial","volume":"22","author":"Apter","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"issue":"6","key":"10.1016\/j.ygyno.2017.04.004_bb0245","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/infdis\/jiv519","article-title":"Cross-protection of the bivalent human papillomavirus (HPV) vaccine against variants of genetically related high-risk HPV infections","volume":"213","author":"Harari","year":"2016","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ygyno.2017.04.004_bb0250","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2017.04.004_bb0260","series-title":"30th International Papillomavirus Conference","article-title":"Human papillomavirus (HPV)-16\/18 AS04 adjuvanted vaccine efficacy in >26year old women: end of study (year 7) results from VIVIANE, a randomized multinational trial.","author":"Wheeler","year":"2011"},{"issue":"10","key":"10.1016\/j.ygyno.2017.04.004_bb0265","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1468-3083.2009.03266.x","article-title":"The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24","volume":"23","author":"Majewski","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"27\u201328","key":"10.1016\/j.ygyno.2017.04.004_bb0270","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ygyno.2017.04.004_bb0275","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1447-0756.2009.01167.x","article-title":"Immunogenicity and safety of human papillomavirus-16\/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women","volume":"36","author":"Bhatla","year":"2010","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"2","key":"10.1016\/j.ygyno.2017.04.004_bb0280","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrclinonc.2015.146","article-title":"HPV-FASTER: broadening the scope for prevention of HPV-related cancer","volume":"13","author":"Bosch","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2017.04.004_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068329","article-title":"Reduced prevalence of oral human papillomavirus (HPV) 4years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica","volume":"8","author":"Herrero","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ygyno.2017.04.004_bb0290","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiu357","article-title":"Reduced prevalence of vulvar HPV16\/18 infection among women who received the HPV16\/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial","volume":"210","author":"Lang Kuhs","year":"2014","journal-title":"J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.ygyno.2017.04.004_bb0295","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(11)70213-3","article-title":"Efficacy of a bivalent HPV 16\/18 vaccine against anal HPV 16\/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial","volume":"12","author":"Kreimer","year":"2011","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2017.04.004_bb0300","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv302","article-title":"Multisite HPV16\/18 vaccine efficacy against cervical, anal, and oral HPV infection","volume":"108","author":"Beachler","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.04.004_bb0305","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/S2214-109X(16)30099-7","article-title":"Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis","volume":"4","author":"Bruni","year":"2016","journal-title":"Lancet Glob. Health"},{"issue":"5","key":"10.1016\/j.ygyno.2017.04.004_bb0310","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect. Dis."},{"issue":"9783","key":"10.1016\/j.ygyno.2017.04.004_bb0315","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(11)60551-5","article-title":"Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study","volume":"377","author":"Brotherton","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ygyno.2017.04.004_bb0320","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S1473-3099(10)70182-1","article-title":"Cervical cancer incidence can increase despite HPV vaccination","volume":"10","author":"Harper","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ygyno.2017.04.004_bb0325","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.canep.2016.04.003","article-title":"Associations between prior HPV4 vaccine doses and cervical cancer screening participation","volume":"42","author":"Boone","year":"2016","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.ygyno.2017.04.004_bb0330","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.pmedr.2015.07.011","article-title":"Adherence to cervical cancer screening varies by human papillomavirus vaccination status in a high-risk population","volume":"2","author":"Paynter","year":"2015","journal-title":"Prev. Med. Rep."},{"key":"10.1016\/j.ygyno.2017.04.004_bb0335","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ypmed.2016.04.004","article-title":"Effect of number of human papillomavirus vaccine doses on guideline adherent cervical cytology screening among 19\u201326year old females","volume":"88","author":"Hirth","year":"2016","journal-title":"Prev. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2017.04.004_bb0340","doi-asserted-by":"crossref","first-page":"279","DOI":"10.5694\/mja14.00021","article-title":"Cervical screening rates for women vaccinated against human papillomavirus","volume":"201","author":"Budd","year":"2014","journal-title":"Med. J. Aust."},{"issue":"5","key":"10.1016\/j.ygyno.2017.04.004_bb0345","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/bjc.2015.473","article-title":"HPV immunisation and increased uptake of cervical screening in Scottish women; observational study of routinely collected national data","volume":"114","author":"Palmer","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"16","key":"10.1016\/j.ygyno.2017.04.004_bb0350","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.vaccine.2014.01.087","article-title":"Does the HPV vaccination programme have implications for cervical screening programmes in the UK?","volume":"32","author":"Beer","year":"2014","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.ygyno.2017.04.004_bb0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134185","article-title":"The participation of HPV-vaccinated women in a National Cervical Screening Program: population-based cohort study","volume":"10","author":"Herweijer","year":"2015","journal-title":"PLoS One"}],"updated-by":[{"DOI":"10.1016\/j.ygyno.2017.08.019","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000}}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817307746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817307746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T06:43:14Z","timestamp":1575614594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817307746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0090825817307746"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.04.004","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HPV vaccines \u2013 A review of the first decade","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}